Ipsen S.A. Company Profile
Ipsen is a global biopharmaceutical group, with sales exceeding 1 billion euros in 2009. The Group has total worldwide staff of more than 4,400 employees, of which nearly 900 contribute to the discovery and development of innovative drugs for patient care. Ipsenâs development strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology, and on primary care drugs. This strategy is supported by an active policy of partnerships. Ipsenâs research & development (R&D) centers and its peptide & protein engineering platform give the Group a strong competitive edge. In 2009, R&D expenditure totaled close to â¬200 million, representing nearly 20% of Group sales. Ipsenâs shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the âService de Règlement Différéâ (âSRDâ). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit our website at www.ipsen.com.
News Articles
To buy or not to buy? Ipsen searches for Inspiration
Ipsen of France has confirmed that its US partner Inspiration Biopharmaceuticals failed to raise third party financing by 30 September 2012. As a result, Ipsen's call option to acquire Inspiration is...
Ipsen signs research accord with Japan's Peptidream
PARIS, April 10 (Reuters) - French pharmaceutical group Ipsen has signed a research partnership with Japan's Peptidream to develop therapeutic peptides for serious diseases in Ipsen's focus areas of n...
Regulatory News: IPSEN (Paris:IPN): IPSEN Société anonyme with a share capital of €84,118,423 Registered office: 65 quai Georges Gorse 92100 Boulogne-Billancourt France 419 838 529 RCS Nanterre...
Inspiration’s Hemophilia Pact With Ipsen Gets Surprise Revamp
Inspiration Biopharma and hemophilia partner Ipsen have renegotiated their nearly three-year-old deal around two late-stage clinical assets. As part of the new deal, Ipsen has given up its option to b...
Ipsen partners with firm in Japan to develop therapeutic peptides
Japan-based PeptiDream and Ipsen agreed to collaborate in the discovery and development of therapeutic peptides for serious m -More-
Ipsen Expects Increlex Supply Interruption
PARIS — Ipsen today announced that the supplier of Increlex®'s (mecasermin [rDNA origin] Injection) active ingredient, Lonza, is facing manufacturing issues with Increlex® at its Hopkinton site (M...
Ipsen and Inspiration Biopharma in deal with Baxter for OBI-1
French drugmaker Ipsen (Euronext: IPN) and privately-held US firm Inspiration Biopharmaceuticals have entered into an asset purchase agreement (APA) whereby Baxter International (NYSE: BAX) agrees to...
Ipsen, Inspiration partner to commercialize IB1001 and OBI-1 for hemophilia
Inspiration Biopharmaceuticals Inc. today announced new license, development and commercialization agreements with its strategic partner, Ipsen.
Drugs and Medications
Somatuline depot [Beaufour Ipsen Pharma SAS]
Somatuline Depot (lanreotide) Injection
PubMed Articles
Somatostatin analogs for the treatment of neuroendocrine tumors.
Somatostatin is an important regulator of endocrine and exocrine secretion, affecting the release of many hormones. The effects of somatostatin are mediated through its interaction with one of five so...
New Trends in the Science of Botulinum Toxin-A as Applied in Dystonia.
ABSTRACT New trends and advances in botulinum toxin neuroscience paved the way to the better understanding of the toxin from its behavior at the bench to the clinics. As details of mechanism of action...
{blacktriangledown}Febuxostat for gout.
Around 1.4% of the UK population have gout, the prevalence of which increases with age to around 3% in women and 7% in men aged over 75 years.1-3 Acute gout is intensely painful and can reduce patient...
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
A number of experimental models of L-DOPA-induced dyskinesia have been proposed, but these models result in a low to medium rate of dyskinetic animals with mild to severe symptoms. The objective of th...
Human MC4R (hMC4R) mutations with in vitro functional effects are responsible for 0.5-2.5% of severe obesity. Designing ligands able to counteract this in vitro associated molecular defect is crucial...
Clinical Trials
Administration of GnRH Antagonist to Oocyte Donation Recipients
This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation h...
Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
The purpose of this study is to compare ovulation induction using a flexible GnRH antagonist protocol and flare up GnRH agonist protocol in IVF patients with poor response to ovarian stimu...
The purpose of this study is to compare pregnancy rates and the occurrence of OHSS in PCOS patients who were treated with GnRH agonist and GnRH antagonist protocols ovarian stimulation dur...
Companies
Ipsen is a global biopharmaceutical group, with sales exceeding 1 billion euros in 2009. The Group has total worldwide staff of more than 4,400 employees, of which nearly 900 cont...
Ipsen is a global biopharmaceutical group with total sales in excess of 1 billion euros in 2009, and total worldwide staff of more than 4,400. Its strategy is based on fast growin...
Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. T...
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively targe...
Funxional Therapeutics Limited
Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced t...
More Information about "Ipsen S.A." on BioPortfolio
We have published hundreds of Ipsen S.A. news stories on BioPortfolio along with dozens of Ipsen S.A. Clinical Trials and PubMed Articles about Ipsen S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ipsen S.A. Companies in our database. You can also find out about relevant Ipsen S.A. Drugs and Medications on this site too.
